Willems, Ruben http://orcid.org/0000-0001-8732-9455
Annemans, Lieven
Siopis, George http://orcid.org/0000-0003-1407-0846
Moschonis, George
Vedanthan, Rajesh
Jung, Jenny http://orcid.org/0000-0002-1774-1177
Kwasnicka, Dominika
Oldenburg, Brian
d’Antonio, Claudia
Girolami, Sandro
Agapidaki, Eirini
Manios, Yannis http://orcid.org/0000-0001-6486-114X
Verhaeghe, Nick http://orcid.org/0000-0001-9956-4970
Usheva, Natalya
Iotova, Violeta
Triantafyllidis, Andreas
Votis, Konstantinos
Toti, Florian
Makrilakis, Konstantinos
Seghieri, Chiara
Moreno, Luis
Dupont, Sabine
Lewis, Leo
Djokic, Djordje
Skouteris, Helen
,
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (945246, 945246, 945246, 945246, 945246, 945246)
Department of Health | National Health and Medical Research Council (APP2007006, APP2007006, APP2007006, APP2007006)
NYU Grossman School of Medicine DigiCare4You funding subaward
Article History
Received: 27 February 2023
Accepted: 7 July 2023
First Online: 18 August 2023
Competing interests
: L.A. received consulting fees from Mundipharma for advice on cost-effectiveness of SGLT2 inhibitors for the management of type 2 diabetes; honoraria from Boehringer Ingelheim and Mundipharma for lectures on health economic aspects of diabetes; is a member of the board of the AstraZeneca Foundation. C.d.A. and S.G. are employees of the company Meteda, manufacturer of MetaClinic, DiaWatch METEDA, MetaDieta and MyDiet. All other authors declare no competing interests.